Skip to main content
. 2011 Aug 1;4(4):249–257. doi: 10.1593/tlo.11136

Table 2.

Comparison of the Effects of CVX-045 and Bevacizumab on Measurable End Points in the A549 Model.

Treatment End Points 1 wk 2 wk 4 wk
PBS
CVX-045 (30 mg/kg 1x/wk) Apoptosis *
MVD
Bevacizumab (5 mg/kg 2x/wk) Apoptosis *
MVD

Apoptosis and MVD were measured as described. Statistical differences were determined using ANOVA with a Bonferroni post test to compare test samples to time-matched PBS-treated controls. MVD indicates microvessel density.

*

P < .05.

P < .001.